BALTIMORE, MD--(Marketwired - May 14, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that the current positioning of Nuvilex Inc. (OTCQB: NVLX) and its proprietary live-cell encapsulation platform delivery system is reminiscent of some of the greatest biotechnology success stories of the past 20 years. Some of the companies that come to mind are Genentech (the "original" biotech) which was acquired by Roche, Inc., Amgen, Inc., and Celgene Corp.

Genentech, which has a major focus on oncology treatments, has some of the largest selling oncology drugs in its arsenal, generating around $12 billion in annual sales alone for the company. It is the success of its platform technology that resulted in its $47 billion acquisition in 2009. Clearly, its broad success in oncology, notably treating pancreatic cancer and breast cancer, which sit atop the Nuvilex (OTCQB: NVLX) to-do list, indicate the huge value the market places on oncology treatment success.

Amgen, the world's largest biotech company with a $78 billion market cap, has grown in part through acquisition and collaborations with many other pharmaceutical firms. The Nuvilex (OTCQB: NVLX) platform delivery system could emerge as an agnostic and broadly used system that is licensed to other firms, for use in their own clinical trials and studies.

The Celgene acquisition of Abraxas Bioscience for $2.9 billion in 2010 appears to be a path that many investors could envision for Nuvilex (OTCQB: NVLX). Abraxas, which was noted for its proprietary tumor targeting technology, was acquired after receiving FDA approval for its lead product to treat breast cancer.

When looking at these leaders, it is clear that collaborations, strategic investments and potential M&A could occur once the Company has an approval in its quiver and other mid-late stage trials, ongoing.

To view a summary of Nuvilex reports or download the reports in their entirety, please visit www.goldmanresearch.com

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.